Senvest Management LLC reduced its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 21.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,192,300 shares of the biopharmaceutical company’s stock after selling 332,319 shares during the quarter. Dynavax Technologies makes up about 1.7% of Senvest Management LLC’s portfolio, making the stock its 25th largest position. Senvest Management LLC owned 1.97% of Dynavax Technologies worth $25,634,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of DVAX. PointState Capital LP acquired a new position in shares of Dynavax Technologies during the 2nd quarter valued at $13,510,000. Lord Abbett & CO. LLC acquired a new position in shares of Dynavax Technologies during the 2nd quarter valued at $7,777,000. GMT Capital Corp lifted its position in shares of Dynavax Technologies by 28.2% during the 2nd quarter. GMT Capital Corp now owns 3,005,137 shares of the biopharmaceutical company’s stock valued at $29,450,000 after acquiring an additional 660,637 shares during the period. Candriam Luxembourg S.C.A. acquired a new position in shares of Dynavax Technologies during the 2nd quarter valued at $5,066,000. Finally, Bain Capital Public Equity Management LLC acquired a new position in shares of Dynavax Technologies during the 2nd quarter valued at $4,741,000. 70.61% of the stock is currently owned by institutional investors.
Dynavax Technologies Corporation (DVAX) opened at $18.40 on Monday. Dynavax Technologies Corporation has a 1-year low of $3.70 and a 1-year high of $24.45.
A number of research analysts recently issued reports on DVAX shares. William Blair reiterated an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies in a research report on Wednesday, August 9th. Royal Bank Of Canada reiterated an “outperform” rating and set a $28.00 target price (up previously from $26.00) on shares of Dynavax Technologies in a research report on Monday, September 25th. Cowen reiterated a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a research report on Friday, November 3rd. ValuEngine downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Cantor Fitzgerald boosted their target price on shares of Dynavax Technologies from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. Dynavax Technologies has an average rating of “Buy” and an average target price of $25.17.
TRADEMARK VIOLATION WARNING: “Senvest Management LLC Has $25.63 Million Stake in Dynavax Technologies Corporation (DVAX)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/12/04/senvest-management-llc-has-25-63-million-stake-in-dynavax-technologies-corporation-dvax.html.
Dynavax Technologies Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
What are top analysts saying about Dynavax Technologies Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dynavax Technologies Corporation and related companies.